



RECEIVED

APR 29 2002

TECH CENTER 1600/2900

Patent

Attorney's Docket No. 003300-737

# 12C  
JMB  
4/30/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of )  
Kjell OLMARKER *et al.* ) Group Art Unit: 1647  
Application No.: 09/760,810 ) Examiner: Jegatheesan Seharaseyon  
Filed: January 17, 2001 )  
For: USE OF CERTAIN DRUGS FOR )  
TREATING NERVE ROOT INJURY )

**RESPONSE TO RESTRICTION REQUIREMENT, REPLY AND AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This paper response to the Restriction Requirement set forth in the Official  
Communication mailed March 26, 2002 (Paper No. 10).

Please amend the above-identified application as follows:

**IN THE CLAIMS:**

Please amend claims 1 and 2 as follows without prejudice or disclaimer.

cl Sub D1  
1. (Amended) A method of treating a nerve disorder in a mammal in need of  
such treatment comprising the step of administering a TNF- $\alpha$  inhibitor wherein said TNF- $\alpha$   
inhibitor is metalloproteinase inhibitors excluding methylprednisolone for the treatment of  
nerve disorders in said mammal in need of such treatment wherein said nerve disorder is  
caused by the liberation of TNF- $\alpha$  and compounds triggered by the liberation of or  
presence of TNF- $\alpha$  by inhibiting TNF- $\alpha$ .

2. (Amended) A pharmaceutical composition for the treatment of a nerve  
disorder in a mammal in need of such treatment comprising a pharmaceutically effective

04/29/2002 RHEBHT 0000053 09760810  
01 FC:203  
252.00 DP

C